Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies

Related Keywords

Boston ,Massachusetts ,United States ,Paris ,France General ,France ,Munich ,Bayern ,Germany ,Belgium ,Amsterdam ,Noord Holland ,Netherlands ,Orsay ,French ,Marie Curie ,Vincent Brichard ,Eliane Piaggio ,Bpifrance Innobio ,Sacha Mann Takeda ,Kostenloser Wertpapierhandel ,Jacques Mizrahi Bioqube ,Pasteur Mutualit ,Institut Curie ,Jean Francois Morin Bpifrance Innobio ,Felice Verduyn Van Weegen ,Dementia Fund ,European Union Under Horizon ,Philippe Monteyne Fund ,Boehringer Ingelheim ,European Fund For Strategic Investments ,Takeda Pharmaceutical Company ,Bioqube Factory Fund ,Takeda Ventures Inc ,Loncode Institute ,European Union ,Life Sciences ,Bioqube Ventures ,Takeda Ventures ,Luc Boblet ,Egle Therapeutics Board ,Jean Francois Morin ,Sacha Mann ,Philippe Monteyne ,Jacques Mizrahi ,Elisa El Nouchi ,Venture Partner ,Aegle Therapeutics ,Investment Director ,Takeda Pharmaceutical Company Limited ,European Biotech ,Innovfin Equity ,European Fund ,Strategic Investments ,Investment Plan ,Executive Officer ,Segle ,Herapeutics ,Raises ,Billion ,Series ,Evelop ,First ,Glass ,Egulatory ,Cells ,Therapies ,Ased ,Greg ,Tarvers ,